NEXGEL Taps Orthobiologics Veteran to Scale BIONX Surgical Sales

Event summary

  • NEXGEL appoints Dave Hazard as VP of Sales for BIONX Surgical on May 13, 2026.
  • Hazard brings 13+ years of orthopedics, spine, and biologics sales leadership.
  • Previously built $50M+ revenue business at Arthrex and 400-rep salesforce at Nuo Therapeutics.
  • BIONX Surgical formed through recent transformative acquisition to scale revenue.

The big picture

This appointment signals NEXGEL's aggressive push to scale its newly acquired BIONX Surgical division, targeting high-growth segments like orthopedics and sports medicine. The move comes as healthcare companies increasingly consolidate biologics capabilities through strategic acquisitions. Hazard's background suggests NEXGEL is prioritizing enterprise partnerships to drive repeatable revenue streams.

What we're watching

Sales Execution
How Hazard's track record in biologics commercialization translates to BIONX Surgical's revenue growth.
Market Penetration
Whether NEXGEL can leverage existing partnerships (Arthrex, Smith+Nephew) to accelerate BIONX Surgical's adoption.
Product Pipeline
The pace at which BIONX Surgical brings new products to market following its formation through acquisition.